Summary
The statements are about a patient savings/eligibility program and income verification, which are not supported by the provided FDA-approved VASCEPA prescribing information excerpts and therefore cannot be verified against the label.
Category Scores
Accurate Statements
Unsupported Statements
The Vascepa savings program is designed for uninsured patients.
Not supported by the provided VASCEPA prescribing information excerpts (which cover drug indications, dosing, contraindications, warnings/precautions, adverse reactions, interactions, and specific populations).
To enroll in the Vascepa savings program, patients must have income at or below 200% of the Federal Poverty Level (FPL).
Not supported by the provided VASCEPA prescribing information excerpts.
The FPL varies by household size and state.
Not supported by the provided VASCEPA prescribing information excerpts.
For a household of one, 200% of the FPL is around $24,280 per year.
Not supported by the provided VASCEPA prescribing information excerpts.
For a household of one, 200% of the FPL is about $2,023 per month.
Not supported by the provided VASCEPA prescribing information excerpts.
Income verification is an automatic process when enrolling in the Vascepa savings program.
Not supported by the provided VASCEPA prescribing information excerpts.
To verify eligibility, applicants are asked to provide proof of income such as a recent tax return or pay stub.
Not supported by the provided VASCEPA prescribing information excerpts.
If a patient's income increases above 200% of the FPL after enrolling in the Vascepa savings program, the patient is no longer eligible for the program.
Not supported by the provided VASCEPA prescribing information excerpts.
Patients with a valid commercial insurance plan that covers Vascepa may also be eligible for savings.
Not supported by the provided VASCEPA prescribing information excerpts.
Income verification is typically not required for patients with a valid commercial insurance plan that covers Vascepa.
Not supported by the provided VASCEPA prescribing information excerpts.
Contradictions
Important Omissions
Any label-supported information regarding a Vascepa savings program, eligibility criteria, income thresholds, enrollment mechanics, or verification requirements.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The provided statements concern patient eligibility for a savings program and include specific eligibility rules (e.g., 200% FPL thresholds and verification processes) that are not supported by the supplied VASCEPA prescribing information excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The response makes multiple claims about a Vascepa savings/assistance program that are not present in the provided FDA-approved VASCEPA prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported drug content (indications, dosing, contraindications, warnings/precautions, adverse reactions, interactions, and supported population information). Do not state savings-program eligibility or enrollment requirements unless that information is included in the provided FDA-approved label text.